Literature DB >> 18199549

Development of a new tracking tool for the human monomeric laminin-gamma 2 chain in vitro and in vivo.

Naohiko Koshikawa1, Tomoko Minegishi, Kazuki Nabeshima, Motoharu Seiki.   

Abstract

Laminin-5 (Ln-5), a heterotrimer composed of three different laminin chains [laminin-alpha 3 (Ln-alpha 3), laminin-beta 3 (Ln-beta 3), and laminin-gamma 2 (Ln-gamma 2)], is a major component of the basement membrane in most adult tissues. One of the chains, Ln-gamma 2, is a specific marker of invasive tumors because it is frequently expressed as a monomer in malignant tumors. However, there is no simple and direct method to detect the monomeric form of Ln-gamma 2 selectively in the presence of Ln-5 because all available antibodies recognize both monomeric and heterotrimeric forms of Ln-gamma 2. In this study, we developed a new monoclonal antibody (mAb) termed 1H3 that reacts specifically with human Ln-gamma 2 monomers during immunoprecipitation, ELISA, Western blotting, and immunostaining. Ln-5 was not recognized by mAb 1H3 after denaturation with detergents under nonreducing conditions, but reactivity was recovered when denaturation was done under reducing conditions. The epitope of the antibody was mapped to region on the coiled-coil structure formed between Ln-gamma 2 and its partner chains Ln-alpha 3 and Ln-beta 3 in Ln-5, whose structure is further stabilized by disulfide bonds. In normal tissue samples, the basement membrane was stained with conventional antibody against Ln-gamma 2 but not by mAb 1H3. In contrast, tumor cells in tissue sections could be stained with mAb 1H3 as efficiently as with conventional antibody. Thus, mAb 1H3 holds promise as a powerful tracking tool for the specific detection of monomeric Ln-gamma 2 in vivo and in vitro and is potentially useful as a diagnostic tool for detecting tumors and as a vehicle for drug delivery to cancer tissues.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18199549     DOI: 10.1158/0008-5472.CAN-07-5269

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Laminin-121--recombinant expression and interactions with integrins.

Authors:  Takako Sasaki; Junichi Takagi; Camilla Giudici; Yoshihiko Yamada; Eri Arikawa-Hirasawa; Rainer Deutzmann; Rupert Timpl; Arnoud Sonnenberg; Hans Peter Bächinger; David Tonge
Journal:  Matrix Biol       Date:  2010-05-23       Impact factor: 11.583

2.  Static magnetic field controls cell cycle in cultured human glioblastoma cells.

Authors:  Seung Chan Kim; Wooseok Im; Jay Yong Shim; Seung-Ki Kim; Beom Jin Kim
Journal:  Cytotechnology       Date:  2016-04-27       Impact factor: 2.058

Review 3.  Defining the role of laminin-332 in carcinoma.

Authors:  Cherise M Guess; Vito Quaranta
Journal:  Matrix Biol       Date:  2009-08-15       Impact factor: 11.583

4.  Expression of laminin 5-γ2 chain in cutaneous squamous cell carcinoma and its role in tumour invasion.

Authors:  H Hamasaki; K Koga; M Aoki; M Hamasaki; N Koshikawa; M Seiki; H Iwasaki; J Nakayama; K Nabeshima
Journal:  Br J Cancer       Date:  2011-08-09       Impact factor: 7.640

5.  Tumor budding and laminin5-γ2 in squamous cell carcinoma of the external auditory canal are associated with shorter survival.

Authors:  Yasuko Okado; Mikiko Aoki; Makoto Hamasaki; Kaori Koga; Takayuki Sueta; Hideki Shiratsuchi; Yoshinao Oda; Takashi Nakagawa; Kazuki Nabeshima
Journal:  Springerplus       Date:  2015-12-24

6.  Development of a fully automated chemiluminescence immunoassay for urine monomeric laminin-γ2 as a promising diagnostic tool of non-muscle invasive bladder cancer.

Authors:  Masatoshi Nakagawa; Takashi Karashima; Masayuki Kamada; Eisaku Yoshida; Toru Yoshimura; Masanori Nojima; Keiji Inoue; Taro Shuin; Motoharu Seiki; Naohiko Koshikawa
Journal:  Biomark Res       Date:  2017-10-13

7.  Serum monomeric laminin-γ2 as a novel biomarker for hepatocellular carcinoma.

Authors:  Hirofumi Kiyokawa; Hiroshi Yasuda; Ritsuko Oikawa; Chiaki Okuse; Nobuyuki Matsumoto; Hiroki Ikeda; Tsunamasa Watanabe; Hiroyuki Yamamoto; Fumio Itoh; Takehito Otsubo; Toru Yoshimura; Eisaku Yoshida; Masatoshi Nakagawa; Naohiko Koshikawa; Motoharu Seiki
Journal:  Cancer Sci       Date:  2017-06-02       Impact factor: 6.716

8.  Novel LAMC2 fusion protein has tumor-promoting properties in ovarian carcinoma.

Authors:  Hoshino Daisuke; Hisamori Kato; Kazuhiro Fukumura; Akila Mayeda; Yohei Miyagi; Motoharu Seiki; Naohiko Koshikawa
Journal:  Cancer Sci       Date:  2021-11-05       Impact factor: 6.716

9.  Urinary laminin-γ2 is a novel biomarker of non-muscle invasive urothelial carcinoma.

Authors:  Masayuki Kamada; Naohiko Koshikawa; Tomoko Minegishi; Chiaki Kawada; Takashi Karashima; Taro Shuin; Motoharu Seiki
Journal:  Cancer Sci       Date:  2015-11-06       Impact factor: 6.716

10.  Highly sensitive detection of invasive lung cancer cells by novel antibody against amino-terminal domain of laminin γ2 chain.

Authors:  Kaoru Miyazaki; Jun Oyanagi; Atsuko Sugino; Hiroki Sato; Tomoyuki Yokose; Haruhiko Nakayama; Yohei Miyagi
Journal:  Cancer Sci       Date:  2016-12-12       Impact factor: 6.716

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.